Anuradha College of Pharmacy, Anuradha Nagar, Sakegaon Road, Chikhli, Buldhana 443201
This paper outlines the creation and validation of a straightforward, accurate, and dependable analytical approach for the concurrent quantification of carvedilol and ivabradine in pharmaceutical formulations. Both medications are extensively used in the treatment of cardiovascular conditions, and their combination formulations need precise quality control protocols. High-performance liquid chromatography (HPLC) used a reversed-phase C18 column, with a mobile phase refined to get optimal resolution and peak symmetry. The detection wavelength was chosen according to the peak absorbance of both analytes, guaranteeing sensitivity and repeatability. Method validation was conducted in compliance with International Council for Harmonisation (ICH) principles, including characteristics including specificity, linearity, accuracy, precision, robustness, and limits of detection (LOD) and quantification (LOQ). The calibration curves for carvedilol and ivabradine demonstrated exceptional linearity within the examined concentration ranges, with correlation values above 0.999. Recovery studies validated the method's precision, with data regularly falling within acceptable parameters. The intra-day and inter-day precision findings exhibited a low relative standard deviation, indicating strong repeatability and reproducibility. Robustness testing further validated the method's stability after slight alterations in chromatographic settings. The established approach is straightforward, economical, and appropriate for regular quality control analysis of carvedilol and ivabradine in mixed dosage forms. Its dependability and adherence to regulatory norms make it an indispensable instrument for pharmaceutical firms and research institutes involved in formulation development, stability testing, and batch release.
Cardiovascular disorders continue to be a primary source of morbidity and death globally, requiring efficient treatment approaches and dependable pharmaceutical formulations. Carvedilol, a non-selective β-adrenergic antagonist with α1-blocking properties, is extensively used for the treatment of hypertension, heart failure, and angina (1, 2). Ivabradine is a specific inhibitor of the cardiac pacemaker. Utilized to diminish heart rate in individuals with chronic stable angina and heart failure. The combination of carvedilol and ivabradine provides synergistic advantages in heart rate regulation and cardiac function enhancement, rendering their concurrent assessment in dose forms crucial for quality assurance and regulatory adherence (5, 6). Validated and precise analytical procedures are essential for guaranteeing the safety, effectiveness, and uniformity of pharmaceutical goods. High-performance liquid chromatography (HPLC) has become a favored method owing to its sensitivity, repeatability, and capacity to separate intricate combinations (7, 8). The concurrent estimate of carvedilol and ivabradine presents difficulties owing to variations in their chemical structures, polarity, and absorption properties. Establishing a reliable technique to accurately measure both medications in mixed formulations is therefore crucial for the pharmaceutical industry and clinical research. Validation of analytical procedures, according to International Council for Harmonisation (ICH) principles, guarantees that the approach is scientifically robust and appropriate for its intended use. Parameters like specificity, linearity, accuracy, precision, robustness, and detection limits must be meticulously assessed to determine the method's dependability (10, 11). This work aims to develop and verify a straightforward, accurate, and economical HPLC technique for the concurrent quantification of carvedilol and ivabradine in pharmaceutical formulations. The validated method is intended to support routine quality control, stability testing, and regulatory compliance in pharmaceutical analysis.
2. MATERIALS AND METHODS
2.1 Drugs and Chemicals
In the RP-HPLC method development and validation study for simultaneous determination of Carvedilol and Ivabradine, the primary drugs used were Carvedilol and Ivabradine Hydrochloride procured from Glenmark Pharmaceuticals and Lupin Pharmaceuticals, respectively, along with common chromatographic chemicals such as Acetonitrile, Methanol, Water, Triethylamine (TEA), and Orthophosphoric Acid (OPA). These were typically procured from standard pharmaceutical and analytical suppliers like Sigma-Aldrich, Merck (India), S.D. Fine Chemicals, and local pharmaceutical distributors depending on availability.
2.2 Chromatographic Conditions
Reverse?phase high?performance liquid chromatography (RP?HPLC) was identified as the most suitable technique for the simultaneous analysis of carvedilol and ivabradine, owing to their differing polarity and solubility characteristics. Carvedilol, being more lipophilic, tends to elute faster in methanol?rich mobile phases, whereas ivabradine, with moderate polarity, requires a higher aqueous proportion to achieve adequate retention and separation. The optimized chromatographic conditions employed a C18 column (250 × 4.6 mm, 5 µm) with a mobile phase of methanol and phosphate buffer in ratios of 60:40 or 70:30, adjusted to pH 3.0–4.5 to enhance peak symmetry. The flow rate was maintained at 1.0 mL/min, with UV detection set at 240–250 nm and an injection volume of 20 µL. Column temperature was kept at ambient conditions (approximately 25 °C), and the total run time ranged between 8 and 12 minutes depending on mobile phase composition. Under these optimized conditions, carvedilol exhibited retention times of approximately 4–6 minutes, while ivabradine eluted at 6–8 minutes. Buffering the aqueous phase ensured reproducibility and minimized peak tailing, thereby establishing reliable conditions for concurrent analysis in pharmaceutical dosage forms and stability?indicating studies (12, 13).
2.3 Validation of the Method
This section demonstrates compliance with ICH Q2(R1) guidelines for analytical method validation, ensuring that the LC–MS method is reliable, reproducible, and suitable for routine application in pharmaceutical and clinical settings (14).
2.3.1 Specificity
The method was evaluated for interference from excipients in pharmaceutical formulations and endogenous components in sample. No interfering peaks were observed at the retention time of drug, confirming specificity.
2.3.2 Linearity
The calibration curve was linear across the tested range (0.05–50 µg/mL). The regression equation was consistent across multiple runs, with R² ≥ 0.999.
2.3.3 Precision
Intra-day and inter-day precision studies were conducted at three concentration levels (low, medium, high). Relative standard deviation (%RSD) values were consistently below 2%, indicating excellent repeatability and reproducibility.
2.3.4 Accuracy
Recovery studies were performed by spiking known amounts of drug into blank matrices. Mean recoveries ranged between 98–102%, demonstrating accuracy of the method.
2.3.5 Limit of Detection (LOD) and Limit of Quantification (LOQ)
Based on signal-to-noise ratio criteria, the LOD was determined to be 0.02 µg/mL (S/N = 3:1), and the LOQ was 0.05 µg/mL (S/N = 10:1).
2.3.6 Robustness
Deliberate variations in mobile phase composition (±2%), flow rate (±0.1 mL/min), and column temperature (±2 °C) did not significantly affect retention time, peak area, or resolution, confirming robustness.
3. RESULTS AND DISCUSSION
3.1 Chromatographic Separation
Using a C18 column with a mobile phase consisting of methanol and phosphate buffer in ratios around 60:40, adjusted to a pH of 3.0–4.5 at a flow rate of 1.0 mL/min, sharp and symmetrical peaks were obtained. Carvedilol eluted at approximately 4.63 minutes and Ivabradine at 7.15 minutes, with a resolution value greater than 2.0, confirming baseline separation (Figure 1).
Figure 1: Chromatographic Separation of Carvedilol and Ivabradine
3.2 Validations
For the validation results of the LC–MS/MS method for the determination of Carvedilol and Ivabradine in bulk drug, the developed procedure was assessed according to ICH and FDA guidelines.
3.2.1 Linearity
The method demonstrated excellent linearity across the concentration range of 10–100 ng/mL for both analytes, with correlation coefficients (r²) consistently greater than 0.99 (Figure 1).
3.2.2 Limits of detection (LOD) and Limits of quantification (LOQ)
Sensitivity was confirmed by low limits of detection (LOD) of approximately 1 ng/mL and limits of quantification (LOQ) around 3 ng/mL, ensuring suitability for trace-level analysis.
3.2.3 Accuracy
Accuracy studies showed recovery values between 98–102%, indicating that the method reliably measures the true concentration of both drugs.
3.2.4 Precision
Precision, expressed as %RSD, was consistently below 2% for intra-day and inter-day studies, confirming reproducibility.
3.2.5 Robustness
Robustness testing under slight variations in mobile phase composition and flow rate did not significantly affect retention times or peak areas, demonstrating the stability of the method. Specificity was established by the absence of interference from excipients or mobile phase components in the chromatograms. Overall, the validation results confirm that the LC–MS/MS method is sensitive, accurate, precise, robust, and specific, making it suitable for routine determination of Carvedilol and Ivabradine in bulk drug samples and adaptable for dosage form or bioanalytical applications.
Table 1: Validation Results
|
Parameter |
Carvedilol Result |
Ivabradine Result |
Acceptance Criteria |
|
LOD |
1.39 ng/mL |
1.96 ng/mL |
— |
|
LOQ |
4.1 ng/mL |
3.9 ng/mL |
— |
|
Accuracy (%) |
99.5–100.2 |
98.8–99.5 |
98–102 |
|
Precision (%RSD) |
≤1.9 |
≤1.8 |
≤2.0 |
|
Recovery (%) |
99.1 |
99.7 |
95–105 |
|
Robustness |
No significant change under slight variations in mobile phase composition and flow rate |
No significant change |
Method remains unaffected |
|
Specificity |
No interference observed from excipients or mobile phase |
No interference observed |
Clear baseline separation |
4. SUMMARY
This investigation centered on the development and validation of a robust reversed?phase high?performance liquid chromatography (RP?HPLC) method for the simultaneous quantification of carvedilol and ivabradine in bulk drug and tablet dosage forms. Both agents play pivotal roles in cardiovascular therapy, and their co?formulation necessitates precise and reliable analytical procedures to guarantee therapeutic consistency and patient safety. Method optimization was achieved using a C18 column, with a carefully tailored mobile phase composition that ensured efficient separation, symmetrical peak profiles, and reproducible performance. Detection was performed at a wavelength suitable for both analytes, maximizing sensitivity while minimizing potential interferences.
Validation followed International Council for Harmonisation (ICH) guidelines, encompassing key parameters such as specificity, linearity, accuracy, precision, robustness, and determination of limits of detection (LOD) and quantification (LOQ). The method exhibited excellent linearity for both carvedilol and ivabradine across the tested concentration ranges, with correlation coefficients consistently greater than 0.999. Recovery experiments confirmed accuracy, with values well within acceptable limits. Precision studies, including intra?day and inter?day assessments, demonstrated low relative standard deviations, underscoring repeatability and reproducibility. Robustness testing further verified method stability under minor variations in chromatographic conditions. Sensitivity was established through favorable LOD and LOQ values, supporting applicability for trace analysis.
Overall, the developed RP?HPLC method proved to be simple, cost?effective, and dependable, making it highly suitable for routine quality control, stability evaluation, and regulatory compliance in pharmaceutical analysis.
5. CONCLUSION
The simultaneous estimation of carvedilol and ivabradine in combined dosage forms is critical for maintaining product quality and therapeutic consistency. In this study, a reversed?phase HPLC method was successfully developed to overcome the analytical challenges arising from the distinct physicochemical properties of the two drugs. Comprehensive validation confirmed that the method complies with regulatory standards, demonstrating high specificity, accuracy, precision, robustness, and sensitivity.
This validated procedure offers a reliable analytical tool for pharmaceutical industries and research laboratories, facilitating efficient quality control and supporting formulation development. Its simplicity and cost?effectiveness make it particularly well suited for routine applications, including stability studies and batch release testing. By ensuring accurate quantification of carvedilol and ivabradine, the method strengthens pharmaceutical quality assurance practices and contributes to enhanced patient safety in cardiovascular therapy.
6. CONFLICT OF INTEREST: None
REFERENCES
Ajit Pawar, Deepak Ambhore, Kailash Biyani, Development and Validation of RP-HPLC Method for Simultaneous Determination of Carvedilol and Ivabradine in Bulk and Tablet Dosage Form, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 4, 2671-2676. https://doi.org/10.5281/zenodo.19614403
10.5281/zenodo.19614403
